US 12,311,024 B2
Cancer cell-targeted drug delivery carrier and composition for promoting photo-thermal treatment effects, both of which contain M1 macrophages as active ingredient
Seung Kuk Baek, Seoul (KR); and Nu Ri Im, Seoul (KR)
Assigned to KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR)
Appl. No. 17/626,043
Filed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR)
PCT Filed Jul. 13, 2020, PCT No. PCT/KR2020/009173
§ 371(c)(1), (2) Date Jan. 10, 2022,
PCT Pub. No. WO2021/010698, PCT Pub. Date Jan. 21, 2021.
Claims priority of application No. 10-2019-0084665 (KR), filed on Jul. 12, 2019.
Prior Publication US 2022/0249666 A1, Aug. 11, 2022
Int. Cl. A61K 41/00 (2020.01); A61K 31/337 (2006.01); A61K 31/44 (2006.01); A61K 31/475 (2006.01); A61K 31/519 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 33/242 (2019.01); A61K 33/243 (2019.01); A61K 40/17 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 47/69 (2017.01); A61P 35/00 (2006.01); C12N 5/0786 (2010.01)
CPC A61K 41/0028 (2013.01) [A61K 31/337 (2013.01); A61K 31/44 (2013.01); A61K 31/475 (2013.01); A61K 31/519 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 33/242 (2019.01); A61K 33/243 (2019.01); A61K 40/17 (2025.01); A61K 40/24 (2025.01); A61K 40/42 (2025.01); A61K 47/6923 (2017.08); A61P 35/00 (2018.01); C12N 5/0645 (2013.01); A61K 2239/31 (2023.05)] 2 Claims
 
1. A method for producing cell targeting anticancer M1 macrophages, the method comprising:
(1) treating isolated undifferentiated macrophages with PMA (Phorbol-12 Myristate 13-Acetate) to induce an M0 macrophages state;
(2) treating the M0 macrophages with IFN-γ (Interferon gamma) at a concentration of 100 to 400 μg,ml for 24 to 48 hours to induce differentiation into the M1 macrophages;
(3) preparing a mixture by mixing an anticancer drug with a photo-responsive material to a final concentration of 1 μg/ml for the photo-responsive material and 2.5 μg/ml for the anticancer drug:
(4) adding the mixture to the culture medium of the M1 macrophages and using an orbital shaker at room temperature for 2 hours to induce incorporation of the photo-responsive material and anticancer drug into the M1 macrophages; and
(5) Centrifuging the culture medium containing the mixture and M1 macrophages to remove the supernatant and obtaining M1 macrophages containing the photo-responsive material and anticancer drug;
wherein the photo-responsive material is PLGA-core gold nanoshells, and the anticancer drug is doxorubicin.